CMOs are working hard to improve performance by investigating new technologies for filtration and purification. Downstream processing problems are not unique to CMOs, of course. It seems, however, ...

Manufacturers are being pushed beyond mAb‑era platforms into a new design model built around molecular engineering, complex ...

Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with potent cytotoxic payloads for targeted oncology. While an ADC consists of an antibody, linker and payload, the ...

Biomanufacturing is different from other processing industries. It is less able to sustain continuous end-to-end flows because it must contend with unique technical, practical, regulatory, and ...

Over two-thirds of biopharmaceutical manufacturers now report that their facility is experiencing capacity bottlenecks due to downstream processing. A number of factors continue to converge to create ...

With multiple, complex chromatographic purification, buffer exchange, and viral inactivation steps, downstream processing of monoclonal antibodies (mAbs) remains the major bottleneck in ...

With the recent FDA approval of the CAR T-cell therapies Kymriah ® from Novartis and Yescarta ® from Kite Pharma, there has been a renewed interest in bioprocessing and the manufacturing facilities ...

Drug development and manufacturing have undergone a seismic shift in the last two decades, 1 from blockbuster small molecules to highly personalized biologics 2 and cell and gene therapies. Because ...

In this brochure, Thermo Scientific takes a closer look at how integrated hot-melt extrusion (HME) workflows, paired with flexible downstream processing technologies from Thermo Fisher Scientific, can ...